Johnson & Johnson evolves its JLABS incubator strategy, shifting from physical lab space to targeted scientific fields. JLABS has incubated approximately 1,200 startups since 2012. The company will now concentrate resources on high-potential research areas that align with its internal drug development pipeline.
This strategic change includes reducing its physical footprint. J&J winds down operations at JLABS sites in New York, Houston, and Toronto.
The company emphasizes virtual memberships. These provide startups with access to J&J's global network, mentorship, and resources without requiring physical residency. This move intends to de-risk investments and better focus on bringing in new, promising science.